Last reviewed · How we verify
JS005
At a glance
| Generic name | JS005 |
|---|---|
| Also known as | Recombinant humanized anti-IL-17A monoclonal antibody injection |
| Sponsor | Shanghai Junshi Bioscience Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Bioequivalence Study of JS005 Pre-filled Syringe and JS005 Auto-injector (PHASE1)
- A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
- A Clinical Study of JS005 in Patients With Ankylosing Spondylitis (PHASE2)
- Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing (PHASE1, PHASE2)
- Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA (PHASE2)
- Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS (PHASE2)
- Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JS005 CI brief — competitive landscape report
- JS005 updates RSS · CI watch RSS
- Shanghai Junshi Bioscience Co., Ltd. portfolio CI